Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

盐酸头孢卡品酯颗粒 - NMPA Drug Approval Details

Approvals/NMPA/Cefcapene Pivoxil Hydrochloride Granules

Approved

化学药品

Cefcapene Pivoxil Hydrochloride Granules

Unknown🇨🇳 National Medical Products Administration

Approval Date: Apr 21, 2026
Approval ID: 8n5SSdTYcsR
Company: Unknown
Type: 化学药品

Approval Details

Approval Id: 8n5SSdTYcsR
Approval Number: 国药准字HJ20260045
Generic Name: 盐酸头孢卡品酯颗粒
Generic Name En: Cefcapene Pivoxil Hydrochloride Granules
Drug Type: 化学药品
Dosage Form: 颗粒剂
Strength: 50mg（按 C₁₇H₁₉N₅O₆S₂计）
Reg Date: 2026-04-21
Expired Date: 2031-04-20

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Apr 21, 2026

Approval ID

8n5SSdTYcsR

Type

化学药品

Back to NMPA Approvals